anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
B‑cell lymphoma is difficult to cure because of its biological and clinical heterogeneity, and due to native chemoresistance. Immunotherapies that overcome cancer‑induced immune evasion have been the center of recent developments in oncology. This is emphasized by the accomplishment of various agents that disrupt programmed cell death protein 1 (PD‑1)‑mediated immune suppression in diverse tumors. However, while PD‑1 blockade has been effective in numerous malignancies, a significant proportion of cancers, including B‑cell lymphoma, show certain rates of primary resistance to these therapeutic strategies. Histone deacetylase inhibitors (HDACis) have exhibited anticancer activity though suppressing cell proliferation, inducing differentiation and triggering apoptosis. The present study aimed to explore a therapeutic strategy combining a HDACi (romidepsin) and PD‑1 blockade (BMS‑1) in B‑cell lymphoma, utilizing a constructed mouse model of B‑cell lymphoma. The IC50 of the two inhibitors was confirmed by MTT assay, and their inhibitory effects were revealed to be dose‑ and time‑dependent. The data demonstrated that the combined treatment of romidepsin and BMS‑1 synergistically inhibited the growth of B‑cell lymphoma. Furthermore, it was revealed that romidepsin and BMS‑1 synergistically triggered apoptosis in mouse B‑cell lymphoma. The synergistic effect of these agents was capable of activating tumor‑infiltrating lymphocytes, particularly CD3+CD4+ and CD3+CD8+ T cells. The results of the present study underscore the potential of HDAC inhibition in conjunction with PD‑1 blockade as a novel therapeutic approach for B‑cell lymphoma, highlighting the synergistic effects of these two mechanisms in enhancing antitumor immunity.
Balanced posture without dizziness is achieved via harmonious coordination of visual, vestibular, and somatosensory systems. Specific frequency bands of center of pressure (COP) signals during quiet standing are closely related to the sensory inputs of the sensorimotor system. In this study, we proposed a deep learning-based novel protocol using the COP signal frequencies to estimate the equilibrium score (ES), a sensory system contribution. Sensory organization test was performed with normal controls (n=125), patients with Meniere's disease (n=72) and vestibular neuritis (n=105). The COP signals preprocessed via filtering, detrending and augmenting during quiet standing were converted to frequency domains utilizing Short-time Fourier Transform. Four different types of CNN backbone including GoogleNet, ResNet-18, SqueezeNet, and VGG16 were trained and tested using the frequency transformed data of COP and the ES under conditions #2 to #6. Additionally, the 100 original output classes (1 to 100 ESs) were encoded into 50, 20, 10 and 5 sub-classes to improve the performance of the prediction model. Absolute difference between the measured and predicted ES was about 1.7 (ResNet-18 with encoding of 20 sub-classes). The average error of each sensory analysis calculated using the measured ES and predicted ES was approximately 1.0%. The results suggest that the sensory system contribution of patients with dizziness can be quantitatively assessed using only the COP signal from a single test of standing posture. This study has potential to reduce balance testing time (spent on six conditions with three trials each in sensory organization test) and the size of computerized dynamic posturography (movable visual surround and force plate), and helps achieve the widespread application of the balance assessment.
The invention provides a sustained-release injection or sustained-release implant containing antibiotics. The sustained-release injection comprises sustained-release microspheres and solvent. The microspheres contain sustained-release adjuvants and antibiotics, and the solvent is a special solvent containing suspending agent such as sodium carboxymethylcellulose and having viscosity of 100-3000cp (20-30 DEG C); and the sustained-release adjuvants are selected from poly(ethylene-co-vinylacetate) (EVAc), polifeprosan, poly(lactic acid) (PLA), poly(lactic-co-glycolic acid) (PLGA), sebacic acid copolymer, albumin glue and gelatin. The sustained-release implant is made from microspheres or by other methods. The sustained-release implant or injection can be locally placed or injected into foci to locally sustained-release the drug for more than 10 days, so as to obtain and maintain local drug effective concentration while remarkably reduce the systemic toxicity of the drug. The sustained-release injection has distinct and unique therapeutic effect on local infection diseases caused by Staphylococci, Streptococci, Peptostreptococcus, Propionibacterium acnes, Enterobacter, Mycobacterium tuberculosis, Gonococcus or Meningococcus, such as chronic osteomyelitis, severe decubital ulcer, refractory skin ulcer, diabetic foot, femoral head necrosis and abscess.
BACKGROUND: Chronic kidney disease (CKD) and its associated end-stage renal disease (ESRD) are significant health problems that pose a threat to human well-being. Renal fibrosis is a common feature and ultimate pathological outcome of various CKD leading to ESRD. The Astragalus mongholicus Bunge and Panax notoginseng formula (A&P) is a refined compound formulated by our research group, which has been clinically administered for over a decade and has demonstrated the ability to improve the inflammatory state of various acute or chronic kidney diseases. However, the underlying mechanism by which A&P ameliorates renal fibrosis remains unclear.
METHODS: We established a mouse model by surgically ligating the unilateral ureter to induce renal injury in vivo. And we utilized renal in situ electroporation of a plasmid with low LncRNA A33 expression to establish the unilateral ureteral obstruction(UUO)mouse model. In vitro, we stimulated primary tubular epithelial cells(pTEC) injury using TGF-β1, siRNA-A33, and pcDNA3.1-A33 plasmids were transfected into pTECs to respectively knockdown and overexpress LncRNA A33, and both in vitro and in vivo models were intervened with A&P.
RESULTS: The results demonstrated that A&P effectively alleviated renal fibrosis in mice. Subsequent findings indicated high expression of LncRNA A33 in the kidneys of UUO mice and TGF-β1-induced renal tubular cells. In situ, renal electroporation of a plasmid with reduced LncRNA A33 expression revealed that inhibiting LncRNA A33 significantly improved renal fibrosis in UUO mice. Moreover, A&P effectively suppressed LncRNA A33 expression both in vitro and in vivo. Subsequent downregulation of LncRNA A33 in renal tubular epithelial cells resulted in the downregulation of numerous fibrotic markers, a significant inhibition of LncRNA A33, and a notable reduction in downstream ferroptosis signaling. Cell experiments demonstrated that A&P improved renal fibrosis in UUO mice by inhibiting LncRNA A33 and downregulating ferroptosis signaling.
CONCLUSION: Through the inhibition of LncRNA A33 and subsequent downregulation of ferroptosis signaling, A&P showed potential as a therapeutic approach for improving renal fibrosis in UUO mice, providing a potential treatment avenue for CKD.
OBJECTIVES: Under optimal conditions, afferent and efferent human skin graft microcirculation can be restored 8-12 days postgrafting. Still, the evidence about the reperfusion dynamics beyond this period in a dermato-oncologic setting is scant. We aimed to characterise the reperfusion of human skin grafts over 4 weeks according to the necrosis extension (less than 20%, or 20%-50%) and anatomic location using laser speckle contrast imaging (LSCI).
METHODS: Over 16 months, all eligible adults undergoing skin grafts following skin cancer removal on the scalp, face and lower limb were enroled. Perfusion was assessed with LSCI on the wound margin (control skin) on day 0 and on the graft surface on days 7, 14, 21 and 28. Graft necrosis extension was determined on day 28.
RESULTS: Forty-seven grafts of 47 participants were analysed. Regardless of necrosis extension, graft perfusion equalled the control skin by day 7, surpassed it by day 21, and stabilised onwards. Grafts with less than 20% necrosis on the scalp and lower limb shared this reperfusion pattern and had a consistently better-perfused centre than the periphery for the first 21 days. On the face, the graft perfusion did not differ from the control skin from day 7 onwards, and there were no differences in reperfusion within the graft during the study.
CONCLUSION: Skin graft reperfusion is a protracted process that evolves differently in the graft centre and periphery, influenced by postoperative time and anatomic location. A better knowledge of this process can potentially enhance the development of strategies to induce vessel ingrowth into tissue-engineered skin substitutes.
Device comprises a reservoir holding a drug and with a surface through which the drug is released into a biological environment, and a metal layer between surface and environment. In a first state the metal layer is impermeable, and in a second permeable, to passage of the drug so that passage is prevented until the layer changes state. The metal state is pref. changed at a controllable rate by reaction with a weak acid, base or oxidising agent, and in partic. sweat when the device is held against the skin for application of nitroglycerin, benzotropine, nicotine, secoverine, propranolol or timolol. Gas evolved as the metal changes state is pref. collected. The device may have a number of reservoirs each with a metal layer between it and the environment.
This placebo SSI was developed to mirror the structure of the Contain COVID Anxiety SSI, discuss COVID-19 related content, and do so without as many of the potential active ingredients of effective SSIs. Participants will receive scientific information about how soap kills the COVID-19 virus, but no neuroscience information related to behaviors or behavior change.
Neutrophil Gelatinase-associated Lipocalin (NGAL) is a acute phase protein which is elevated in conditions like acute kidney injury and myocardial infarction. When a coronary artery is occluded, detrimental changes occur in myocardial vessels. After relief of the occlusion, blood flow to the heart may still be impeded, a phenomenon known as "no-reflow". Data is lacking on factors associated with early detection of patients at risk for this phenomenon, and early stratification of this group seems vital since the no-reflow phenomenon is associated with worse outcomes. The investigators hypothesized that there might be an association between higher NGAL levels and the occurrence of no-flow findings, and that NGAL might serve as a marker of worse prognosis in this population. The investigators also hypothesized that NGAL levels might serve as a marker of early acute kidney injury and that there might be specific patterns of NGAL levels over time in different subsets of patients. The aim of the study is to determine the association between NGAL levels at admission and during the first days after a ST-elevation myocardial infarction, the occurrence of the no-reflow phenomenon, the extent of myocardial damage ascertained by cardiac imaging techniques (echocardiography and cardiac resonance imaging). Data regarding patients' clinical, laboratory, electrocardiogram, coronary angiography and percutaneous coronary intervention, in-hospital and 30-day follow-up after discharge will be recorded.
The sedentary protocol will follow the same four phases as the intervention protocol only the patient will remain in the supine position on the Sara Combilizer®. Ideally, no interventions will occur during the 70-minute protocol. If medications are given or other interventions are necessary, this will be registered.
PCT No. PCT/JP79/00296 Sec. 371 Date Jul. 20, 1980 Sec. 102(e) Date Jul. 3, 1980 PCT Filed Nov. 16, 1979 PCT Pub. No. WO80/01039 PCT Pub. Date May 29, 1980.This invention relates to a new fibrinolytic substance and the method of manufacturing the same which can be singly isolated from venom of venomous snakes belonging to the family of Trimeresurus taxonomically by means of molecular sieve chromatography and ion exchange chromatography. This substance has the action of dissolving fibrin in mammals by activating plasminogen and its clinical use a fibrinolytic agent is promising.
Cerebral infarction, also known as ischemic stroke, is caused by various regional blood supply disorders in the brain tissue, leading to ischemic hypoxic lesions and necrosis of the brain tissue and then the corresponding clinical manifestations of neurological loss, which has high mortality and disability. This study comprehensively reviews the potential molecular mechanisms of TRPC6 in neuroprotection in cerebral infarction and provides a summary of TRPC6 as a targeted drug or prognostic biomarker for cerebral infarction patients. We will screen and synthesize evidence about the molecular mechanisms of TRPC6 in cerebral infarction from the current literature to obtain comprehensive knowledge on this topic. In the pathogenesis, neuroinflammation and intracellular calcium accumulation play an important role in the onset and development of cerebral infarction. Transient receptor potential cation channel subfamily C6 (TRPC6) is the main component of calcium store-operated calcium channels. It plays a central role in ischemic cerebrovascular disease by mediating the calcium ion signaling pathway. In this review, evidence on the neuroprotective effects of TRPC6 has been shown, including inhibiting neuroinflammation and inhibiting nerve cell apoptosis, thereby alleviating nerve injury. However, at the same time, TRPC6 promotes inflammation in other organs. Generally, although an increasing number of researches support the protective role of TRPC6 in cerebral infarction, there is still evidence showing that overexpression of TRPC6 increases inflammatory tissue damage in other organs. Therefore, clarifying the molecular mechanism of TRPC6 will help develop targeted drugs or prognostic biomarkers for cerebral infarction to promote and predict neurological function recovery. More evidence to elucidate the molecular mechanism of TRPC6 in cerebral infarction is needed. Enriching TRPC6 in neuroinflammation areas and modifying its cell specificity might be the orientation of drug development that increases the effect of stroke treatment and reduces the impact on other organs. In conclusion, in cerebral infarction, TRPC6 has been proven to alleviate neuroinflammation and inhibit nerve cell apoptosis. However, at the same time, TRPC6 may promote inflammation in other organs. Therefore, the targeting potential of TRPC6 in cerebral infarction needs to be further explored.
PURPOSE:To obtain a plaster for external use having moderate moisture permeability and excellent sealing effect, by using a supporting base composed mainly of a resin composition consisting of a vinyl chloride-ethylene copolymer, an ethylene-carbon monoxide-vinyl acetate copolymer and a hydrated aluminosilicate. CONSTITUTION:100 pts. wt. of a vinyl chloride-ethylene copolymer is compounded with 5-200 pts. wt., preferably 15-80 pts. wt. of an ethylene- carbon monoxide-vinyl acetate copolymer and 0.5-10 pts. w., preferably 1-5 pts. wt. of a hydrated aluminosilicate and the obtained resin composition is used as a supporting base of the objective plaster. The ethylene content of the vinyl chloride-ethylene copolymer is preferably 4-8 wt% and the hydrated aluminosilicate is preferably A-type zeolite. Since the supporting base has moderate sealing property and moisture-permeability, it has excellent sealing effect, high skin migration and transcutaneous absorbability. It has high flexibility and is free from skin irritation and lowering of drug action.
The aim of the present study was to evaluate the effect of caffeic acid phenethyl ester (CAPE) pretreatment used as matrix metalloproteinase (MMP) inhibitor on microtensile bond strength (µTBS) of nanohybrid resin restorations applied with total-etch or self-etch adhesive systems. A total of 10 patients aged between 12 and 18 years old (4 males, 6 females, mean age:15) received 40 composite restorations. The patients who had contralateral pairs of caries-free premolars which were planned to be extracted for orthodontic treatment were enrolled in the study. This study was performed with a protocol approved by the Ethical Committee for Clinical Studies, Faculty of Medicine, University of Ege, Izmir, Turkey (04.10.2012; no:12-8/6). The treatments were performed after the informed consents were received both from the parents and the patients. Included teeth were in function and no anomalies were found neither in teeth nor in occlusion. Two standard cavities (3 x 3 x 4 mm) with continuous enamel cavosurface margins were prepared on the occlusal surfaces of each premolar tooth.Totally four cavities in each patient were randomly assigned into four treatment groups (n=10); Group TC: CAPE and total-etch adhesive (Syntac; Ivoclar Vivadent AG), Group T: Total-etch adhesive (control), Group SC: CAPE and self-etch adhesive (AdheSE; Ivoclar Vivadent AG), Group S: Self-etch adhesive (control). All cavities were restored incrementally with a nano-filled hybrid composite resin (Tetric-N-Ceram, Ivoclar Vivadent AG) in which polymerization in each layer was performed for 40 seconds with a light-curing unit (BluePhase Ivoclar Vivadent AG) exceeding an energy output of 500mw/sec.
FIELD: medicine, narcology. SUBSTANCE: method involves administration of potentiated morphine obtained by multiple successive dilution and shaking by homeopathic procedure. The parent substance is morphine (mixture of opium alkaloids containing 50-95 wt. -% morphine, morphine hydrochloride, apomorphine). Administration of potentiated morphine is combined with habitual narcotic obtained by homeopathic procedure at period of acute intoxication and abstinent symptoms. EFFECT: enhanced effectiveness of treatment. 3 cl
NBI-98854 100 mg administered as two (2) 50 mg capsules taken every morning between 7:00am - 10:00am for 2 weeks. After 2 weeks, NBI-98854 50 mg administered by two (2) 25 mg capsules by mouth, taken every morning between 7:00am - 10:00am for remaining 4 weeks.
The present invention relates to a probe for detecting hydrogen sulfide in vivo. Particularly, the present invention relates to a probe for detecting hydrogen sulfide, which comprises a complex to which a radioisotope Cu. According to the present invention, an animal model, in which a large amount of hydrogen sulfide participating in various diseases is generated, is used to carry out real-time observation through optical and nuclear medicine imaging. As a result, the probe for detecting hydrogen sulfide according to the present invention is bound selectively to hydrogen sulfide and can selectively imagine a portion where hydrogen sulfide is increased abnormally in cells or tissues. Thus, the probe does not affect the anatomic characteristics of a body portion to allow discovery of a disease at a non-predictable part. In addition, the probe for detecting hydrogen sulfide has a high reaction rate with hydrogen sulfide, thereby solving the problem of the conventional imaging agent which requires a predetermined time lapse after administration and before carrying out a test. Therefore, the probe according to the present invention is useful for diagnosis of diseases as an imaging composition or imaging system.
Participants received 6 mg/kg voriconazole (VOR) IV twice per day (BID) on Day 1, and then received 4 mg/kg VOR IV BID on Day 2 until clinically stable when participants transitioned to oral therapy with VOR capsules or VOR placebo capsules BID for up to 12 weeks of treatment. Most participants were expected to initiate treatment with IV therapy and transition to oral therapy as clinically indicated, with some participants initiating treatment with oral therapy, per clinical judgment.
Atrial fibrillation (AF) and anthracyclines are known risk factors for heart failure (HF). The magnitude of the effect of preexisting AF (preanthracycline AF) and newly developed AF (postanthracycline AF) in patients treated with anthracyclines on the occurrence of HF is unknown. The aim of our study was to characterize the impact of preanthracycline and postanthracycline AF on the subsequent occurrence of HF in patients treated with anthracyclines. In 5,598 patients treated with new anthracycline therapy at a tertiary center between 2008 and 2021, propensity score matching was used to match 204 pairs with or without preanthracycline AF and 135 pairs with or without postanthracycline AF. The primary outcome was new-onset symptomatic HF defined by the American Heart Association/American College of Cardiology guidelines. Patients with and without preanthracycline and postanthracycline AF were well matched for age, gender, medications, and cardiovascular risk factors. A total of 45 patients with preanthracycline AF and 23 matched patients developed HF (5-year cumulative incidence: 29% in the preanthracycline AF group and 13% in the matched group, p = 0.003; hazard ratio 2.1, 95% confidence interval 1.3 to 3.4, p = 0.004). A total of 161 patients (2.9%) developed postanthracycline AF. A total of 39 patients (5-year cumulative incidence: 40%) with postanthracycline AF and 9 matched patients (5-year cumulative incidence: 7%) developed HF (hazard ratio 6.1, 95% confidence interval 3.0 to 12.4, p <0.001). Preanthracycline AF and postanthracycline AF are associated with a high incidence of subsequent HF in patients treated with anthracyclines. Prospective studies of therapies are required to decrease HF in these high-risk patients.
The invention discloses polypeptide and coded sequences of fungal thioredoxin and a preparation method and application thereof. The coded sequences of the isolated polypeptide are a nucleotide sequence as shown in SEQ ID NO.1 and an amino acid sequence as shown in SEQ ID NO.2. The preparation method comprises the following steps: firstly, the total RNAs of agrocybe aegeritas are extracted as templates, cDNA first chains are obtained by RT-PCR as templates, and PCR products are obtained by PCR amplification; secondly, PCR products and prokaryotic expression carriers are obtained by enzyme digestion so as to construct and recombine the expression carriers; thirdly, the obtained recombined expression carriers are used for transforming colon bacillus host cells so as to obtain recombined cells expressing the agrocybe aegerita thioredoxin; fourthly, the inducing culture is carried out on the recombined cells, staying over so as to obtain saturated culture; fifthly, proteins are purified and separated by Ni<2+> affinity chromatography, and the polypeptides expressed in the recombined cells are purified. The polypeptides can be applied to the application of medicaments for treating or preventing tumor disease. The related proteins have antitumor activity. The invention has great application value in the development of antitumor medicaments.
PURPOSE:To provide the titled remedy enabling the administration of a large amount of garlic extract and effective to promote the metabolism of lipid and to control the body weight. CONSTITUTION:The objective lipid metabolism promoting agent enables the peroral administration of 1,000-2,500mg of garlic extract component daily. Garlic extract component, especially Oxoamidin (product of Riken Chemical Ind. Ltd.) is a drug effective to promote the physical strength of a patient of tuberculosis and alleviate various diseases such as scrofulosis, valetudinarianism, etc., by the administration at a dose of 100-200mg daily. The administration of a large amount of the agent is expected to be effective to promote the metabolic function of the body, promote the metabolism of excess fat in the body and decrease the body weight owing to the metabolism-promoting function amoung various functions of the agent. Actually, the decrease in body weight or girth was attained in nearly 90% of the cases without using particular defatted diet. Since the agent can be administered without causing any pain or side effect, it is useful for the control of the body weight to remedy and prevent adult ailments.